George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

11 Jun 2020 07:00

RNS Number : 6484P
Midatech Pharma PLC
11 June 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

 

Midatech Pharma Plc

 

Oddfellows House

19 Newport Road

Cardiff CF24 0AA

United Kingdom

 

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Acacia Research Corporation

City and country of registered office (if applicable)

Irvine, California, United States of America

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

09/06/2020

6. Date on which issuer notified (DD/MM/YYYY):

10/06/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

9.91%

9.91%

39,252,557

Position of previous notification (if

applicable)

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary shares of £0.001 each

GB00BKT14T00

3,891,284

9.91%

SUBTOTAL 8. A

3,891,284

9.91%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Acacia Research

Corporation

9.91%

9.91%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

New York, New York, USA

Date of completion

09/06/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLFBMITMTBBMAM
Date   Source Headline
27th Feb 20194:40 pmRNSSecond Price Monitoring Extn
27th Feb 20194:35 pmRNSPrice Monitoring Extension
27th Feb 201910:52 amRNSHolding(s) in Company
26th Feb 201911:26 amRNSFinalisation of Licence Agreement
25th Feb 201912:23 pmRNSResult of the General Meeting and Board changes
8th Feb 20194:39 pmRNSPosting of Circular and Notice of General Meeting
4th Feb 20196:32 pmRNSResult of Placing
4th Feb 20193:16 pmRNSProposed Placing and Open Offer
29th Jan 20199:23 amRNSStrategic Investment & Licence Agreement
25th Jan 20197:00 amRNSFDA feedback on clinical plan for MTD201
15th Jan 20191:56 pmRNSHolding(s) in Company
15th Jan 20199:36 amRNSHolding(s) in Company
11th Jan 201910:58 amRNSHolding(s) in Company
10th Jan 201911:15 amRNSMidatech announces EUR 1.5 million loan facility
20th Dec 20187:00 amRNSCorporate update and potential fundraise
20th Dec 20187:00 amRNSMidatech Announces Microsphere Partnership
28th Nov 20181:17 pmRNSHolding(s) in Company
20th Nov 201812:59 pmRNSHolding(s) in Company
5th Nov 20189:55 amRNSHolding(s) in Company
1st Nov 20185:48 pmRNSNASDAQ Minimum Bid Price Extension
1st Nov 20187:00 amRNSCompletion of Midatech Pharma US Sale
15th Oct 201812:17 pmRNSResult of General Meeting
28th Sep 201810:04 amRNSPosting of Circular and Notice of General Meeting
27th Sep 20187:01 amRNSInterim Results
27th Sep 20187:00 amRNSProposed Sale of Midatech Pharma US Inc
6th Sep 20187:00 amRNSNotice of Interim Results
31st Aug 20187:00 amRNSInterim results from MTD201 exploratory study
1st Aug 20187:00 amRNSIssue of Equity for Midatech Share Incentive Plan
25th Jul 20187:00 amRNSTrading Update
23rd Jul 20187:00 amRNSUS Co-Promotion Agreement
27th Jun 201810:56 amRNSResult of AGM
8th Jun 20187:00 amRNSMidatech US enrols patient in Gelclair trial
1st Jun 20187:00 amRNSBoard change
1st Jun 20187:00 amRNS2017 Annual Report and AGM Notification
25th May 20187:00 amRNSMidatech commences US clinical study with MTX110
21st May 20187:00 amRNSMidatech commences dosing in equivalence study
8th May 20187:00 amRNSSEC filing regarding share price movement
3rd May 201812:15 pmRNSMidatech Announces Receipt of NASDAQ Notice
3rd May 20187:00 amRNSStmnt re Share Price Movement
2nd May 20184:40 pmRNSSecond Price Monitoring Extn
2nd May 20184:35 pmRNSPrice Monitoring Extension
23rd Apr 20187:00 amRNSFinancial results for year ended 31 December 2017
9th Apr 20188:25 amRNSNotice of Results
15th Mar 20187:00 amRNSChanges in Senior Management Team
28th Feb 20187:00 amRNSMidatech gets Orphan Drug Designation for MTD119
14th Feb 20187:00 amRNSTrading Update
16th Jan 20187:00 amRNSIND approval for DIPG treatment MTX110
9th Jan 20187:00 amRNSQ-Octreotide first in-human EU study approved
3rd Jan 20181:36 pmRNSHolding(s) in Company
2nd Jan 20187:00 amRNSMidatech Loan Agreement with MidCap Financial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.